293 related articles for article (PubMed ID: 21700764)
1. Prostate cancer immunotherapy.
May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy: a therapeutic revolution against prostate cancer?].
Pracht M; Herrera F; Tawadros T; Berthold D
Rev Med Suisse; 2013 May; 9(387):1070-5. PubMed ID: 23757912
[TBL] [Abstract][Full Text] [Related]
3. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
4. Current status of immunological approaches for the treatment of prostate cancer.
Drake CG; Antonarakis ES
Curr Opin Urol; 2012 May; 22(3):197-202. PubMed ID: 22328018
[TBL] [Abstract][Full Text] [Related]
5. The evolving role of immunotherapy in prostate cancer.
Gerritsen WR
Ann Oncol; 2012 Sep; 23 Suppl 8():viii22-7. PubMed ID: 22918924
[TBL] [Abstract][Full Text] [Related]
6. Beyond sipuleucel-T: immune approaches to treating prostate cancer.
Cheng ML; Fong L
Curr Treat Options Oncol; 2014 Mar; 15(1):115-26. PubMed ID: 24402184
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer.
Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
Singh BH; Gulley JL
Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
[TBL] [Abstract][Full Text] [Related]
9. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
Antonarakis ES
Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638
[No Abstract] [Full Text] [Related]
10. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
[TBL] [Abstract][Full Text] [Related]
11. Emerging Immunotargets and Immunotherapies in Prostate Cancer.
Montironi R; Santoni M; Sotte V; Cheng L; Lopez-Beltran A; Massari F; Matrana MR; Moch H; Berardi R; Scarpelli M
Curr Drug Targets; 2016; 17(7):777-82. PubMed ID: 26898309
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in prostate cancer: review of the current evidence.
Fernández-García EM; Vera-Badillo FE; Perez-Valderrama B; Matos-Pita AS; Duran I
Clin Transl Oncol; 2015 May; 17(5):339-57. PubMed ID: 25480118
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
Comiskey MC; Dallos MC; Drake CG
Curr Oncol Rep; 2018 Aug; 20(9):75. PubMed ID: 30120592
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer as a model for tumour immunotherapy.
Drake CG
Nat Rev Immunol; 2010 Aug; 10(8):580-93. PubMed ID: 20651745
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Oudard S; Thibault C; Angelergues A; Tartour E; Timsit MO; Mejean A; Michel C; Vano Y
Bull Cancer; 2016 Nov; 103 Suppl 1():S144-S150. PubMed ID: 28057178
[TBL] [Abstract][Full Text] [Related]
16. The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.
Pennock GK; Chow LQ
Oncologist; 2015 Jul; 20(7):812-22. PubMed ID: 26069281
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.
Gulley JL; Madan RA; Heery CR
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714490
[TBL] [Abstract][Full Text] [Related]
18. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer.
Wada S; Jackson CM; Yoshimura K; Yen HR; Getnet D; Harris TJ; Goldberg MV; Bruno TC; Grosso JF; Durham N; Netto GJ; Pardoll DM; Drake CG
J Transl Med; 2013 Apr; 11():89. PubMed ID: 23557194
[TBL] [Abstract][Full Text] [Related]
19. Cancer immunotherapy: sipuleucel-T and beyond.
Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for metastatic prostate cancer: immuno-cold or the tip of the iceberg?
Laccetti AL; Subudhi SK
Curr Opin Urol; 2017 Nov; 27(6):566-571. PubMed ID: 28825923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
